Chernett Jorey purchased $41K of STIM

Chernett Jorey purchased 18,000 shares of Neuronetics, Inc. (STIM) at $2.27 on 2026-10-30.

Original reporting
SEC EDGAR · Chernett Jorey
Published Nov 2, 2026, 1:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 2:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$STIM
Neutral
high confidence
Mentioned
$STIM
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STIMNeutralLow
01

Why it matters

The trade is modest and unlikely to move the stock materially.

02

Market read

A small insider buy that may slightly influence short‑term sentiment but carries low trading relevance.

03

What to watch

Potential upcoming clinical data or regulatory events not disclosed.

Relevance 4/10Novelty 4/10Timing: post‑market filing today

Background

Form 4 filings disclose insider trades; this is the first public report of this purchase.

Company-level read

Ticker impact

$STIMNeutralHigh confidence
Context

Form 4 shows insider Chernett Jorey bought 18,000 shares of Neuronetics at $2.27, a $40.9K purchase.

Expected impact

minor upward pressure as market prices in insider confidence

Evidence & confidence

Purchase size is modest relative to float; impact limited but may signal confidence.

Market effects

None significant; Neuronetics operates in neurostimulation devices.

No broader regional effect.

Limited to investors tracking insider activity.

Counterpoint

Insider purchase may be routine portfolio rebalancing, not a bullish signal.

Key entities

  • Neuronetics, Inc.

    Medical device company listed on NASDAQ (STIM).

  • Chernett Jorey

    10% owner of Neuronetics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$STIMHigh

Why is Neuronetics stock tumbling today?

Neuronetics Inc's stock fell 11.4% in pre-market trading after pricing a $30M share offering at a discount. The company aims to use proceeds to address going concern risks and meet a $15M loan prepayment deadline by November 30, 2026. Despite Q3 revenue growth, these factors drove the decline, with no broader market impact.

$STIMHigh

Neuronetics stock tumbles 10% on stock offering launch

Neuronetics Inc (STIM) shares dropped 10% in after-hours trading after announcing a public stock offering and a credit agreement amendment. The company aims to sell shares with a 30-day option for underwriters to buy 15% more. The amendment reduces revenue covenants if certain conditions are met by November 30, 2026, addressing going concern risks. William Blair, BTIG, and Canaccord Genuity are managing the offering.

$STIMHigh

Neuronetics Inc (STIM) (Q3 2026) Earnings Call Highlights: Revenue Jumps

Neuronetics Inc (STIM) reported Q3 2026 revenue of $42M, up 12.5% YoY, driven by Greenbrook's 20.1% growth. Gross margin expanded to 52.2%, and operating expenses decreased 12.6%, leading to positive adjusted EBITDA of $1.9M. NeuroStar revenue grew only 1.8% YoY, with session revenue declining. Cash balance decreased to $27.9M. Management expects full-year 2026 cash flow to be negative $10M to $12M.

$STIMMed

Neuronetics Q3 Earnings Call Highlights

Neuronetics reported Q3 revenue growth driven by record system sales, with capital and lease units making up over half of sales. The company expects lower treatment-session revenue as it shifts focus to larger customers. Neuronetics anticipates higher growth in 2027 and beyond. It also submitted a 510(k) application for an accelerated TMS protocol and cited a study showing treatment gaps do not reduce effectiveness.